Edition:
United Kingdom

Melinta Therapeutics, Inc. (MLNT.OQ)

MLNT.OQ on NASDAQ Stock Exchange Global Select Market

14.90USD
19 Jan 2018
Change (% chg)

$0.25 (+1.71%)
Prev Close
$14.65
Open
$14.65
Day's High
$14.95
Day's Low
$14.40
Volume
22,993
Avg. Vol
39,816
52-wk High
$24.25
52-wk Low
$10.50

Select another date:

Thu, Jan 18 2018

BRIEF-Melinta Therapeutics Says ‍Partner Commenced New Program For Topical Formulation Of Radezolid, In Preparation For Submitting IND Application To FDA

* MELINTA THERAPEUTICS - ‍PARTNER COMMENCED NEW PROGRAM FOR A TOPICAL FORMULATION OF RADEZOLID, IN PREPARATION FOR SUBMITTING AN IND APPLICATION TO FDA Source text for Eikon: Further company coverage:

BRIEF-Melinta Therapeutics Files For Resale Of Up To 6.9 Mln Shares By Selling Stockholders

* MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 6.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING‍​ Source text: (http://bit.ly/2EqugN6) Further company coverage:

BRIEF-Melinta Therapeutics Files For Resale Of Up To 3.3 Mln Shares By Selling Stockholder

* MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text for Eikon: (http://bit.ly/2CO48LP) Further company coverage:

BRIEF-Deerfield Management Reports 10 Pct Passive Stake In Melinta Therapeutics

* DEERFIELD MANAGEMENT COMPANY LP REPORTS A 10 PCT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN 5 - SEC FILING Source text for Eikon: (http://bit.ly/2Eqi9zA) Further company coverage:

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

BRIEF-Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company

* MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY Source text for Eikon: Further company coverage:

Select another date: